Gláucia Alves de Souza, MD

Medical Oncology Fellow at Hospital Israelita Albert Einstein

[Allison Fitzgerald, MD, PhD @allisonoconn]

I think a big problem here is that medical school only exposes people to inpatient oncology, which is a wildly different (and sadder) world from outpatient oncology- which is like 90% of cancer care. So students have an incorrect idea of what practicing oncology is like.

[The Oncologist @OncJournal]

Molecular tumor boards are key in NSCLC: complete metabolic response with fourth-line capmatinib after reclassification of the oncogenicity of a MET fusion. @gustavoschv
https://t.co/zM5Lu6XzHD

[Yakup Ergün @dr_yakupergun]

Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline

🔹️ BRCA1/2 testing recommended for newly diagnosed breast cancer patients aged ≤65 and select cases >65

🔹️ Recurrent breast cancer patients eligible for PARP inhibitor therapy should undergo BRCA1/2 testing, irrespective of family history

🔹️ Women developing a second primary breast cancer are advised to consider BRCA1/2 testing

🔹️ Prior breast cancer patients, especially those ≤65, should consider testing to understand personal and family risk

🔹️Testing for high/moderate-penetrance genes based on family history is suggested

https://t.co/5buq05Poly

[Camila Braganca Xavier @CamilaBragancaX]

Germline testing🧬 should be revisited for many cancer types to improve #cancercare. This ⁦⁦@ASCO⁩ update frames a beautiful work on the recommendations for #BreastCancer patients w/ the contribution of the 🇧🇷oncogenetic leader Maria Isabel Achatz https://t.co/aPNgR9qvzt

[Roberto Pestana, MD, PhD @PestanaRC]

It is a great pleasure to share the first publication of our #sarcoma group within @LACOG_group, discussing challenges and opportunities for sarcoma care and research in Latin America.

Hope you enjoy the read, let's work to change the paradigm in Fig 2!

https://t.co/w6W9Yg1cgJ

[Eric K. Singhi, MD @lungoncdoc]

Lung cancer STAGING takes the CENTER STAGE at #WCLC23 🥁

9th edition updates:
▪️T: No changes
▪️N: N2 ➡️ N2a (☝️station N2) & N2b (Multistation N2)
▪️ M: M1c ➡️ M1c1 (Multi extrathoracic mets,☝️organ) & M1c2 (Multi extrathoracic mets, multiple organs)

@OncoAlert @IASLC #lcsm

[Toni Choueiri, MD @DrChoueiri]

Paper 10:

Phase 3 RUBY trial shows benefit of adding PD-1 inhibitor #dostarlimab to carboplatin and paclitaxel in patients with primary advanced or recurrent #endometrial cancer. In dMMR–MSI-H cohort, 2-year PFS: 61.4% vs 15.7% (HR 0.28). @NEJM

https://t.co/QAkLNAmP70

[Toni Choueiri, MD @DrChoueiri]

Paper 9:

Mutant IDH1/2 inhibitor #Vorasidenib, improved PFS in patients with residual or recurrent grade 2 IDH-mutant glioma vs. placebo. mPFS, 27.7 vs. 11.1 months (HR: 0.39) @NEJM

https://t.co/ZjGSfAF7Uf

[Toni Choueiri, MD @DrChoueiri]

Paper 8:

Encouraging data from this phase II trial of #Futibatinib, a covalent FGFR1-4 inhibitor, that revealed 42% ORR for previously treated patients with FGFR2-rearranged unresectable or metastatic intrahepatic #cholangiocarcinoma @NEJM

https://t.co/5YkpY2VY5G

[Toni Choueiri, MD @DrChoueiri]

Paper 7:

In patients with resectable stage III/IV melanoma, neoadjuvant+adjuvant #pembrolizumab showed significantly higher EFS than adjuvant alone with no additional toxicity. 2-year EFS: 72% vs 49%. Trial led by the amazing @DrSapnaPatel @NEJM

https://t.co/NKAOzvIFkq

[Toni Choueiri, MD @DrChoueiri]

Paper 6:

RET inhibitor #Selpercatinib showed ⬆️PFS (HR = 0.28) and treatment failure-free survival (HR = 0.25) vs. cabozantinib / vandenatinib in patients with RET–mutant medullary #thyroid cancer. @NEJM

https://t.co/qiihdhuy5O

[Toni Choueiri, MD @DrChoueiri]

Paper 5:

Adjuvant #osimertinib shows ⬆️OS in patients with completely resected, EGFR-mutated, stage IB to IIIA #NSCLC, according to the #ADAURA trial. #ASCO23 #Tsuboi @DrRoyHerbstYale @NEJM
https://t.co/3xVSWMaEph

[Toni Choueiri, MD @DrChoueiri]

Paper 4:

Addition of #pembrolizumab to chemotherapy provided survival benefit in metastatic HER2-negative #gastric or GE junction adenocarcinoma compared to placebo. mOS in ITT: 12.9 vs 11.5 months (HR 0.78). @TheLancetOncol

https://t.co/ht6xb8WWs7

[Toni Choueiri, MD @DrChoueiri]

Paper 3:

Addition of #bevacizumab to trifluridine–tipiracil resulted in ⬆️ OS in patients with refractory metastatic colorectal cancer. mOS: 10.8 vs 7.5 months (HR 0.61). @NEJM #Prager @TaberneroJosep @julientaieb

https://t.co/YrL8SWWwsR

[Toni Choueiri, MD @DrChoueiri]

Paper 2:

Phase 3 trial of KRAS G12C inhibitor #sotorasib + #panitumumab demonstrated ⬆️ PFS in patients with chemo-refractory metastatic colorectal cancer.

@NEJM @mgfakih @FilippoPietran4

https://t.co/8WyOZcAh84

[Toni Choueiri, MD @DrChoueiri]

In this phase 3 trial, the addition of #pembrolizumab to standard paclitaxel plus carboplatin chemotherapy in advanced #endometrial cancer resulted in 70% decrease in disease progression or death in #dMMR cohort. @NEJM @rne_md @aghajanc

https://t.co/CnZ80QnLYN

[Oncology Brothers @OncBrothers]

Summary of 5 new drugs/indications in GI malignancies that were @FDAOncology @US_FDA approved in 2023:

- #Tucatinib - Mountaineer
- #TAS102 + #Bevacizumab - Sunlight
- #Pembro + Cis/Gem - KN966
- #Fruquintinib - FRESCO2
- #Pembro + Chemo - KN859

#OncTwitter #gism #crcsm

[Gláucia Alves de Souza, MD @glaucia_asc]

@andrepcdc @cityofhope @montypal @hosp_einstein I am very grateful to you, Doctor André, for all your help and guidance. It was an incredible discussion. The City of Hope team is impeccable, represented by Doctor Sumanta.

[André Paternò Castello Dias Carneiro @andrepcdc]

Very nice discussion today around papillary renal cell carcinoma with the @cityofhope dream team represented by the amazing @montypal. Congrats @glaucia_asc for the presentation 🇧🇷🇺🇸

[SBOC @SBOC_Oncologia]

Chegou ao fim o 2º bloco da Gincana Nacional de Oncologia para Residentes! O vencedor desta etapa foi o Dr. Osvaldo Pina de Albuquerque Neto, que faz a sua especialização no Instituto de Medicina Integral Professor Fernando Figueira, em Recife (PE).